Suzhou Yinuowei Pharmaceutical Technology

InnoVen (Suzhou Yinuowei Pharmaceutical Technology) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule drugs for challenging targets. Headquartered in Suzhou, China, the company specializes in targeting protein-protein interactions (PPIs) that play critical roles in cancer progression. Its lead program, INV-1008, is a potent and selective MDM2-p53 inhibitor currently undergoing Phase 1 clinical trials for the treatment of solid tumors and hematological malignancies. InnoVen utilizes a proprietary structure-based drug discovery platform to design high-affinity molecules for targets previously considered undruggable. The company's leadership team includes experienced industry veterans from global pharmaceutical companies like Amgen and Sanofi. InnoVen is backed by top-tier venture capital firms, including Lilly Asia Ventures and Qiming Venture Partners.